CRO Industry
During the last 3 decades the Clinical Research industry has grown from a few small industrial providers offering a pressure valve to the pharmaceutical industry to a well established massive industry, growing by 10-15% per annum and employing around 100,000 specialists in a multitude of CRO companies globally.
An increase in Pharmaceutical Research Business’, amalgamations and acquisitions which has directed to the pattern of some very large multinational companies utilisaing as many as 15,000 personal globally. However, the market place is as varied and as open for new ventures as it has been for decades; just very larger in size.
sadly, one of the biggest drivers for the growth of this industry has been the ever increasing rigid requirements rather than an enhancement in real innovation. Yet new approaches in drug development such as personalised medicines and the development of biological medicines will certainly change the clinical research industry. It is likely however to continue to thrive but more in terms of size and diversity.
Entering unexpored regions is the base of all research and as such requires a constantly widening range of specialists who can add to the new challenges within clinical research.
Partnerships and close alliances have been the buzzword of the industry over many years and indeed it would seem like the logical evolution. Whilst other industries have embraced this concept it has not really materialised in the pharmaceutical research market.The processes by which clinical trial services are purchased have become smarter and more structured. The demand for standardised procedures dealing with large quantities of tests and data in some areas of full drug development have created a massive requiremenst and the subsequent formation of large and process driven Clinical Research Organisations regularly supplying the major pharmaceutical companies. However, large processing units are not the most suitable environments for true innovation and it is not surprising that formidable pharmaceutical organisations constantly scout for fresh alliances in the biotech and Clinical Research industry.
Innovation is the product of brilliance usually delivered by an individual. However, large development programmes are reliant on large infrastructures. These are very different needs that the industry has and it is unlikely that they will ever be efficiently met by any one CRO company.
However large the portfolio of a CRO may be, the forte of any large organisation is the ability to process large amounts of goods or clinical data management in a uniform way. The advantage of smaller companies is their ability to adapt to new challenges quickly and deliver true innovation. It follows that the diversity we currently see in the CRO market place is likely to continue providing the opportunities for new entrants to the market|However big the Clinical Research Industry is, the strong point of any formidable company is to have consistency with processing large amounts of products, services or data .
the current political moves towards motivating more patients to put themselves forward for trials, does require reassurances to the public with regard to the safety of those Clinical trials London. The number of regulations is likely to increase which will in turn create an increase in bureaucracy. This again will create a demand for larger organisations to process large amounts of data creating very large databases. Yet more regulations do not necessarily make research safer as the recent unprecedented tragedy at Northwick Park Hospital in London has shown. In this instance all relevant regulations were followed yet the information available was not evaluated in the appropriate way and as a consequence a far too high dose was given to a group of six previously healthy volunteers. The challenge in controlling such complex issues is to find and involve a highly specialised expert in a particular field and to ensure that all available data is evaluated appropriately in the approval process. This represents a challenge, and in this instance, again, size will not be the answer.
Innovation and research require a large arsenal of research tools and services as well as an effectively functioning network, facilitating the access to and exchange of information, both on available services and expertise. It is the creation of these knowledge based networks which will create the most exciting opportunities for the future of a diverse and thriving Clinical Research market.
Sphere: Related Content
Comments(0)